X
[{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Beijing Aosaikang Pharmaceutical","pharmaFlowCategory":"D","amount":"$62.8 million","upfrontCash":"$11.4 million","newsHeadline":"China licence agreement for Feraccru\/Accrufer","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australia\u2019s Therapeutic Goods Administration (TGA) Approves Feraccru\u00ae to Treat Iron Deficiency With or Without Anaemia in Adults","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Hematology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Ferric Maltol
Filters
Companies By Therapeutic Area
Details:
The commercial stage pharmaceutical company focused on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol) confirmed to investors that the TGA has registered Feraccru® as a treatment in the Australian Register of Therapeutic Goods.
Lead Product(s):
Ferric Maltol
Therapeutic Area: Hematology
Product Name: Feraccru
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 09, 2021
Details:
Shield Therapeutics enters into an exclusive licence agreement for its lead product Feraccru®/Accrufer® with Beijing Aosaikang Pharmaceutical Co. Ltd. .
Lead Product(s):
Ferric Maltol
Therapeutic Area: Hematology
Product Name: Undisclosed
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Beijing Aosaikang Pharmaceutical
Deal Size: $62.8 million
Upfront Cash: $11.4 million
Deal Type: Licensing Agreement
January 08, 2020